Bisphosphonates for Osteoporosis in Nonmetastatic Prostate Cancer Patients Receiving Androgen-deprivation Therapy: A Systematic Review and Meta-analysis

Ding, Hui; Yang, Li; Du, Wan; Teng, Yang; Fu, Sheng-Jun; Tao, Yan; Lu, Jian-Zhong; Wang, Zhi-Ping

추천

검색

자료유형: 학술저널

저자정보: Ding, Hui (Institute of Urology, Key Laboratory of Diseases of Urological System, Gansu Province, Gansu Nephro-Urological Clinical Center) Yang, Li (Institute of Urology, Key Laboratory of Diseases of Urological System, Gansu Province, Gansu Nephro-Urological Clinical Center) Du, Wan (Otolaryngological Department, The Second Hospital of Lanzhou University) Teng, Yang (The People's Hospital of Rizhao Donggang Qu) Fu, Sheng-Jun (Institute of Urology, Key Laboratory of Diseases of Urological System, Gansu Province, Gansu Nephro-Urological Clinical Center) Tao, Yan (Institute of Urology, Key Laboratory of Diseases of Urological System, Gansu Province, Gansu Nephro-Urological Clinical Center) Lu, Jian-Zhong (Institute of Urology, Key Laboratory of Diseases of Urological System, Gansu Province, Gansu Nephro-Urological Clinical Center) Wang, Zhi-Ping (Institute of Urology, Key Laboratory of Diseases of Urological System, Gansu Province, Gansu Nephro-Urological Clinical Center)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제14권 제5호

발행연도: 2013.1

수록면: 3,337 - 3,343 (7page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

This systematic review was conducted to assess the efficacy and safety of bisphosphonates for prevention and treatment of osteopenia or osteoporosis in men with non-metastatic prostate cancer receiving androgendeprivation therapy. We searched for randomised controlled trials (RCTs) of bisphosphonates compared with placebo from Pubmed, Embase, the Cochrane Library, and ISI - Science Citation Index. Meta-analyses of prespecified outcomes (bone mineral density, fractures, and adverse events) were performed using Review Manager. Ten RCTs with a total patient population of 1,017 were identified. There was generally more improvement in bone mineral density of the lumbar spine for patients who received bisphosphonate treatment than placebo or other medical treatment at 12 months (WMD 6.02,95%CI 5.39 to 6.65). Similar effects were also observed for total hip, trochanter or femoral neck bone mineral density. However, there was no significant reduction in fractures. Fever and gastrointestinal symptoms were the most common adverse events (10.4% vs. 1.2%; 0.10% vs. 0.03%). Currently, our meta-analysis suggested that oral and intravenous bisphosphonates caused a rapid increase in spine and hip or femoral BMD in non-metastatic prostate cancer patients receiving androgen-deprivation therapy. Fever and gastrointestinal symptoms were common with the use of bisphosphonates. These short-term trials (maximum of 12 months) did not show fracture reduction. In future, more efficient performance of higher quality, more rigorous, large sample, long-term randomised controlled trials (>12 months) are needed where outcomes are detailed.

#Bisphosphonates #osteoporosis #prostate cancer #androgen-deprivation therapy #meta-analysis

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요